Internal link ProQR to Participate in 8th Annual Evercore Healthcare Conference December 01, 2025 at 01:00 PM UTC
Internal link ProQR Announces Third Quarter 2025 Operating and Financial Results November 06, 2025 at 12:00 PM UTC
Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 October 20, 2025 at 12:00 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences in October 2025 October 13, 2025 at 12:30 PM UTC
Internal link ProQR Announces Second Quarter 2025 Operating and Financial Results August 07, 2025 at 11:00 AM UTC
Internal link ProQR Announces Upcoming Presentation at RNA Editing Summit July 28, 2025 at 12:00 PM UTC
Internal link ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP June 26, 2025 at 08:30 PM UTC
Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences May 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results May 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference May 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 May 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth April 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results March 13, 2025 at 11:00 AM UTC
Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa December 11, 2019 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa November 21, 2019 at 12:00 PM UTC
Internal link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 November 06, 2019 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares October 18, 2019 at 12:20 PM UTC
Internal link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares October 16, 2019 at 03:17 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares October 15, 2019 at 09:15 PM UTC
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 October 15, 2019 at 08:08 PM UTC
Internal link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10 October 11, 2019 at 10:02 AM UTC
Internal link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients October 10, 2019 at 10:00 AM UTC
Internal link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO October 07, 2019 at 11:00 AM UTC